Literature DB >> 26776666

Completion thyroidectomy and total thyroidectomy for differentiated thyroid cancer: Comparison and prediction of postoperative hypoparathyroidism.

Xiaofei Wang1,2, Tengfei Xing1, Tao Wei1, Jingqiang Zhu1.   

Abstract

BACKGROUND: Consensus regarding the difference of postoperative hypoparathyroidism following completion thyroidectomy (CT) and total thyroidectomy (TT) has yet to be reached. We compare the occurrence of postoperative hypoparathyroidism between CT and TT for differentiated thyroid cancer (DTC), and explore the predictive factors for postoperative hypoparathyroidism.
METHODS: We retrospectively reviewed 221 consecutive patients underwent CT or TT for DTC between February 2012 and March 2014. Patients' demographic and clinical data of the two groups were analyzed.
RESULTS: There were 57 CTs and 164 TTs. Temporary hypoparathyroidism occurred in 12.3% (7 of 57) and 28.0% (46 of 164) of patients in the CT and TT groups, respectively. In univariate analysis, type of surgical procedure (CT or TT) and extent of central lymph node dissection (CND) (unilateral or bilateral) were significantly associated with the postoperative temporary hypoparathyroidism (P < 0.05). Multivariate analysis showed that only the extent of CND was an independent risk factor for temporary hypoparathyroidism.
CONCLUSIONS: Although temporary hypoparathyroidism was lower in the CT group, our analysis indicates the difference is due to the extent of CND rather than type of surgical procedure (CT vs. TT). Only bilateral CND is an independent risk factor for temporary hypoparathyroidism after thyroidectomy. J. Surg. Oncol. 2016;113:522-525.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  completion thyroidectomy; differentiated thyroid cancer; hypoparathyroidism; total thyroidectomy

Mesh:

Year:  2016        PMID: 26776666     DOI: 10.1002/jso.24159

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Prevalence and risk factors for hypoparathyroidism following total thyroidectomy in Spain: a multicentric and nation-wide retrospective analysis.

Authors:  Juan J Díez; Emma Anda; Julia Sastre; Begoña Pérez Corral; Cristina Álvarez-Escolá; Laura Manjón; Miguel Paja; Marcel Sambo; Piedad Santiago Fernández; Concepción Blanco Carrera; Juan C Galofré; Elena Navarro; Carles Zafón; Eva Sanz; Amelia Oleaga; Orosia Bandrés; Sergio Donnay; Ana Megía; María Picallo; Cecilia Sánchez Ragnarsson; Gloria Baena-Nieto; José Carlos Fernández García; Beatriz Lecumberri; Manel Sahún de la Vega; Ana R Romero-Lluch; Pedro Iglesias
Journal:  Endocrine       Date:  2019-07-17       Impact factor: 3.633

2.  Prolonged Duration of Surgery Predicts Postoperative Hypoparathyroidism among Patients Undergoing Total Thyroidectomy in a Tertiary Referral Centre.

Authors:  Emilie Sonne-Holm; Christoffer Holst Hahn
Journal:  Eur Thyroid J       Date:  2017-04-24

3.  The Ongoing Debate Regarding Completion Thyroidectomy Versus Primary Thyroid Surgery for Low and Intermediate Differentiated Thyroid Carcinoma: A Meta-Analysis.

Authors:  Hyder Mirghani; Ibrahim A Altedlawi Albalawi
Journal:  Cureus       Date:  2020-12-11

4.  Evaluation of Autofluorescence in Identifying Parathyroid Glands by Measuring Parathyroid Hormone in Fine-Needle Biopsy Washings.

Authors:  Zhen Liu; Run-Sheng Ma; Jun-Li Jia; Tao Wang; Dao-Hong Zuo; De-Tao Yin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-21       Impact factor: 5.555

5.  Vitamin D Insufficiency Predicts Susceptibility of Parathyroid Hormone Reduction after Total Thyroidectomy in Thyroid Cancer Patients.

Authors:  Yan Zhang; Weihui Zheng; Yuanyuan Huang; Chao Chen
Journal:  Int J Endocrinol       Date:  2021-12-15       Impact factor: 3.257

6.  Preoperative vitamin D deficiency and postoperative hypocalcemia in thyroid cancer patients undergoing total thyroidectomy plus central compartment neck dissection.

Authors:  Xiaofei Wang; Jingqiang Zhu; Feng Liu; Yanping Gong; Zhihui Li
Journal:  Oncotarget       Date:  2017-05-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.